CYP1A2 Cancer Research Results

CYP1A2, CYP1A2: Click to Expand ⟱
Source:
Type:
CYP1A2, cytochrome P450 enzyme
– CYP1A2 contributes to the metabolism of xenobiotics and can bioactivate pro-carcinogens into DNA-damaging compounds.


Scientific Papers found: Click to Expand⟱
1152- Api,    Does Oral Apigenin Have Real Potential for a Therapeutic Effect in the Context of Human Gastrointestinal and Other Cancers?
- Analysis, Nor, NA
*BioAv↓, Half-Life∅, *BioAv↓, Dose∅, Synergy↑, CYP1A2↓, CYP2C9↓, CYP3A4↓,
9173- ITCs,  SFN,    Dietary isothiocyanates and anticancer agents: exploring synergism for improved cancer management
- Review, Var, NA
Synergy↑, AntiCan↑, chemoP↑, ChemoSen?, toxicity↓, ROS↑, NRF2↑, NF-kB↓, CYP1A1↓, CYP1A2↓, CYP1B1↓, TumCCA↑, PI3K↓, Akt↓, mTOR↓, PTEN↑, BAX↑, ChemoSen↑, Synergy↑, Synergy↑, Synergy↑, Synergy↑, Synergy↑, Dose↝, Synergy↑,
2906- LT,    Luteolin, a flavonoid with potentials for cancer prevention and therapy
- Review, Var, NA
*Inflam↓, AntiCan↑, antiOx⇅, Apoptosis↑, TumCP↓, TumMeta↓, angioG↓, PI3K↓, Akt↓, NF-kB↓, XIAP↓, P53↑, *ROS↓, *GSTA1↑, *GSR↑, *SOD↑, *Catalase↑, *other↓, ROS↑, Dose↝, chemoP↑, NF-kB↓, JNK↑, p27/CDKN1B↑, P21↑, DR5↑, Casp↑, Fas↑, BAX↑, MAPK↓, CDK2↓, IGF-1↓, PDGF↓, EGFR↓, PKCδ↓, TOP1↓, TOP2↓, Bcl-xL↓, FASN↓, VEGF↓, VEGFR2/KDR/Flk1↓, MMP9↓, Hif1a↓, FAK↓, MMP1↓, Twist↓, ERK↓, P450↓, CYP1A1↓, CYP1A2↓, TumCCA↑,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx⇅, 1,   NRF2↑, 1,   ROS↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

FASN↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   BAX↑, 2,   Bcl-xL↓, 1,   Casp↑, 1,   DR5↑, 1,   Fas↑, 1,   XIAP↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 2,   EGFR↓, 1,   ERK↓, 1,   JNK↑, 1,   MAPK↓, 1,   mTOR↓, 1,   PI3K↓, 2,   PKCδ↓, 1,   PTEN↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

P53↑, 1,   TOP1↓, 1,   TOP2↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   P21↑, 1,   p27/CDKN1B↑, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

IGF-1↓, 1,   TumCP↓, 1,  

Migration(tgid=13) ⓘ

FAK↓, 1,   MMP1↓, 1,   MMP9↓, 1,   PDGF↓, 1,   TumMeta↓, 1,   Twist↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   Hif1a↓, 1,   VEGF↓, 1,   VEGFR2/KDR/Flk1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

NF-kB↓, 3,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen?, 1,   ChemoSen↑, 1,   CYP1A1↓, 2,   CYP1A2↓, 3,   CYP1B1↓, 1,   CYP2C9↓, 1,   CYP3A4↓, 1,   Dose↝, 2,   Dose∅, 1,   Half-Life∅, 1,   P450↓, 1,   Synergy↑, 8,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 2,   chemoP↑, 2,   toxicity↓, 1,  
Total Targets: 56

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↑, 1,   GSR↑, 1,   ROS↓, 1,   SOD↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   GSTA1↑, 1,  
Total Targets: 8

Scientific Paper Hit Count for: CYP1A2, CYP1A2
1 Apigenin (mainly Parsley)
1 Isothiocyanates
1 Sulforaphane (mainly Broccoli)
1 Luteolin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:0  prod#:%  Target#:1129  State#:%  Dir#:1
wNotes=0 sortOrder:rid,rpid

 

Home Page